It’s a rigorous inspection that confirms our labs adhere to the strictest quality standards for conducting the CorrectChemo test.
Nashville, Tennessee (PRWEB) June 02, 2015
DiaTech Oncology, provider of CorrectChemo®, the industry leading functional drug response profiling test to help oncologists provide personalized cancer treatment, has gained accreditation from the College of American Pathologists (CAP) for its laboratories in the U.S. and Canada.
“Receiving the CAP certification is equivalent to the ‘Good Housekeeping’ seal of approval,” says Robert E. Henry, president and chief executive officer for DiaTech. “It’s a rigorous inspection that confirms our labs adhere to the strictest quality standards for conducting the CorrectChemo test.”
The CorrectChemo assay, developed by DiaTech, is the only diagnostic test available that identifies, within 72 hours, how effective a variety of chemotherapy drugs may be in killing cancer cells in an individual patient sample. This patient-specific cancer testing provides oncologists with a unique data set to develop a treatment plan tailored to each patient’s individual chemotherapy needs. Clinically published studies have shown that utilization of the test results in improved survival rates, including a 28 percent increase for breast cancer patients and a 68 percent increase for ovarian cancer patients.
DiaTech’s labs in Franklin, Tenn., and Montreal, Canada already have CLIA (Clinical Laboratory Improvement Amendments 1988) regulatory approval, which is required by CMS Medicare. The CAP certification is a step beyond CLIA and requires a lengthy application process and onsite laboratory inspections. DiaTech’s CAP listing for both of its labs can be found here.
Based in Franklin, Tenn., Diatech Oncology is a privately held life sciences and clinical pathology laboratory company that offers patient-specific chemotherapy testing to help oncologists determine the best cancer treatment plans for their patients. DiaTech utilizes a patented technology called the Microculture Kinetic (MiCK) assay, which measures apoptosis (cell death) induced in a specific patient’s cancer cells by chemotherapy. Now called CorrectChemo, the test evaluates the chemotherapeutic drug effect for a specific patient and can tell which chemotherapy drugs are most effective in inducing cancer cell death. It is also used to determine the effectiveness of new drugs in preclinical trials for the pharmaceutical industry. DiaTech has CLIA and CAP certified laboratories in Franklin, Tenn. and Montreal, Canada.